Cumberland Pharmaceuticals Inc. (CPIX)
NASDAQ: CPIX · Real-Time Price · USD
3.460
-0.060 (-1.70%)
At close: Mar 6, 2026, 4:00 PM EST
3.500
+0.040 (1.16%)
After-hours: Mar 6, 2026, 6:41 PM EST
CPIX Revenue
Cumberland Pharmaceuticals had revenue of $13.68M in the quarter ending December 31, 2025, with 31.08% growth. This brings the company's revenue in the last twelve months to $41.28M, up 12.21% year-over-year. In the year 2024, Cumberland Pharmaceuticals had annual revenue of $37.87M, down -4.26%.
Revenue (ttm)
$41.28M
Revenue Growth
+12.21%
P/S Ratio
1.27
Revenue / Employee
$453,608
Employees
91
Market Cap
52.35M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 37.87M | -1.68M | -4.26% |
| Dec 31, 2023 | 39.55M | -2.46M | -5.85% |
| Dec 31, 2022 | 42.01M | 6.03M | 16.75% |
| Dec 31, 2021 | 35.99M | -1.46M | -3.89% |
| Dec 31, 2020 | 37.44M | 3.05M | 8.88% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Assertio Holdings | 137.35M |
| Rockwell Medical | 75.58M |
| InterCure | 72.16M |
| Aytu BioPharma | 62.64M |
| Zhengye Biotechnology Holding | 21.46M |
| SCYNEXIS | 20.60M |
| TherapeuticsMD | 2.80M |
| BioXcel Therapeutics | 752.00K |
CPIX News
- 3 days ago - Cumberland Pharmaceuticals Inc. (CPIX) Q4 2025 Earnings Call Prepared Remarks Transcript - Seeking Alpha
- 3 days ago - CUMBERLAND PHARMACEUTICALS REPORTS 31% FOURTH QUARTER 2025 REVENUE GROWTH - PRNewsWire
- 10 days ago - Joint U.S. Commercialization of RedHill's Talicia® Commences - PRNewsWire
- 10 days ago - CUMBERLAND PHARMACEUTICALS LAUNCHES U.S. PROMOTION OF TALICIA® - PRNewsWire
- 10 days ago - CUMBERLAND PHARMACEUTICALS TO ANNOUNCE 2025 ANNUAL FINANCIAL RESULTS & COMPANY UPDATE - PRNewsWire
- 4 weeks ago - Cumberland Pharmaceuticals Receives FDA Fast Track Designation for its Ifetroban Duchenne Muscular Dystrophy Program - PRNewsWire
- 3 months ago - CALDOLOR® (IBUPROFEN) INJECTION CMS ISSUED J-CODE NOW ASSOCIATED WITH REIMBURSEMENT PRICE SUPPORTING NON-OPIOID PAIN MANAGEMENT - PRNewsWire
- 4 months ago - Cumberland Pharmaceuticals Inc. (CPIX) Q3 2025 Earnings Call Transcript - Seeking Alpha